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Functional genomics identiﬁes type I interferon
pathway as central for host defense against
Candida albicans
Sanne P. Smeekens1,2,*, Aylwin Ng3,4,*, Vinod Kumar5,*, Melissa D. Johnson6,7, Theo S. Plantinga1,2,
Cleo van Diemen5, Peer Arts8, Euge`ne T.P. Verwiel8, Mark S. Gresnigt1,2, Karin Fransen5,
Suzanne van Sommeren5, Marije Oosting1,2, Shih-Chin Cheng1,2, Leo A.B. Joosten1,2, Alexander Hoischen8,
Bart-Jan Kullberg1,2, William K. Scott9, John R. Perfect6,7, Jos W.M. van der Meer1,2, Cisca Wijmenga5,
Mihai G. Netea1,2 & Ramnik J. Xavier3,4
Candida albicans is the most common human fungal pathogen causing mucosal and systemic
infections. However, human antifungal immunity remains poorly deﬁned. Here by integrating
transcriptional analysis and functional genomics, we identiﬁed Candida-speciﬁc host defence
mechanisms in humans. Candida induced signiﬁcant expression of genes from the type I
interferon pathway in human peripheral blood mononuclear cells. This unexpectedly promi-
nent role of type I interferon pathway in anti-Candida host defence was supported by addi-
tional evidence. Polymorphisms in type I interferon genes modulated Candida-induced
cytokine production and were correlated with susceptibility to systemic candidiasis. In in vitro
experiments, type I interferons skewed Candida-induced inﬂammation from a Th17 response
towards a Th1 response. Patients with chronic mucocutaneous candidiasis displayed defective
expression of genes in the type I interferon pathway. These ﬁndings indicate that the type I
interferon pathway is a main signature of Candida-induced inﬂammation and has a crucial role
in anti-Candida host defence in humans.
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C andida albicans is a commensal microorganism thatinhabits human skin and mucosa. Candida can be isolatedfrom up to 70% of the general population at any given
moment, and it is believed that all individuals have been
colonized with Candida at a some point1. Although it is a
commensal organism, C. albicans can also cause mucosal and
systemic infections, especially in immunocompromised hosts2.
Despite the availability of novel classes of antifungal agents (for
example, azoles, echinocandins), mortality due to systemic
candidiasis, the fourth most common form of sepsis3–5, reaches
37–44% (refs 3,6,7). In addition, vaginal and oral candidiasis can
also occur in healthy or only mildly immunocompromised
individuals8, with up to 5% of women in the general population
suffering from recurrent vulvovaginal candidiasis9.
Despite the introduction of modern antifungal drugs and
intensive care facilities, progress in improving the outcome of
Candida infections in the last decade has been disappointing.
Given this lack of progress, it is currently believed that only
adjuvant immunotherapy will be able to further reduce the
burden of morbidity and mortality caused by C. albicans
infections10. Understanding the host defence pathways involved
in candidiasis is therefore crucial for identifying novel targets for
immunotherapy. To date, all investigations aimed at identifying
antifungal host defence mechanisms in humans have relied on
candidate-target approaches that are based on biologic
plausibility of hypotheses extracted from in vitro or animal
studies. Although this approach has been fruitful in conﬁrming
important pathways of antifungal defence, it has lacked the power
to provide a hierarchy of the importance of these pathways, and
to identify potentially novel and unexpected host defence
mechanisms against Candida.
In the present study, we have taken an alternative, unbiased
approach to this biological problem. Using a combination of
transcriptional analysis and systems biology, we have stimulated
human primary cells with the fungus, identifying Candida-
speciﬁc transcription proﬁles in human immune cells. Although
C. albicans induced the transcription of multiple inﬂammatory
gene sets commonly stimulated by other inﬂammatory stimuli, it
also speciﬁcally induced several additional gene sets, among
which we identiﬁed an unexpectedly strong type I interferon
(IFN) signature proﬁle. We conﬁrmed the importance of the type
I IFN pathway for anti-Candida host defence in humans through
immunological and genetic studies in both healthy volunteers and
in patients with systemic candidiasis or suffering from chronic
mucocutaneous candidiasis (CMC).
Results
C. albicans induces a type I IFN response. We measured gen-
ome-wide transcriptional proﬁles in peripheral blood mono-
nuclear cells (PBMCs) from healthy volunteers upon stimulation
with C. albicans, as well as with inﬂammatory stimuli unrelated to
fungal pathogens: Escherichia coli-derived lipopolysaccharide
(LPS), Borrelia burgdorferi, Mycobacterium tuberculosis (MTB)
and RPMI culture medium as a control. Measurements were
performed at 4 and 24 h. A total of 693 transcripts that showed
42-fold higher expression compared with corresponding RPMI
stimulation were selected (Benjamini and Hochberg’s (BH)-
adjusted Po0.05). K-means analysis identiﬁed proﬁle clusters
that indicated shared and speciﬁc genes that were differentially
expressed in response to each stimulus. We grouped shared genes
into signatures representing common early response genes
(clusters 1, 6, 14, 27), common late response genes (clusters 2, 3)
and common inﬂammatory genes induced by all stimulations
(clusters 9, 21, 25) (Fig. 1a and Supplementary Figs S1–S3).
More importantly, to identify a set of discriminatory features
(from the 693 differentially expressed transcripts) that would be
most informative of the state of Candida stimulation and could
distinguish Candida stimulation from the other inﬂammatory
stimuli, we utilized information gain (Kullback–Leibler
divergence/relative entropy) feature selection, to reduce the
dimensionality of the feature space11,12. We performed 10-fold
cross-validation that stratiﬁes the data into 10 random partitions
in which each (in turn) is held out for testing and the remainder
for training a Bayesian classiﬁer. Class prediction was evaluated by
computing the area under the receiver-operating characteristic
curve, which assesses true- and false-positive rates. A 101-
transcript (95-gene) Candida-response signature (Fig. 1b and
Supplementary Table S1) was deﬁned using this supervised
learning approach for class prediction, achieving an area under
the receiver-operating characteristic curve of 97.8%, which would
indicate an excellent classiﬁer performance with very high
discriminative value. Principal component analysis of the
Candida-response signature further demonstrated good class
separation on the basis of Candida status and stimulation
duration (Fig. 1c). As a set, the 101 features collectively identify
expression signatures that are informative of Candida stimulation
across the 4, 24-h or both time points that sufﬁciently distinguish
Candida from the rest. Enrichment analysis for the 101 transcript
Candida-response signature revealed a striking overrepresentation
of the IFN signalling pathway (P¼ 3.8 10 35) (Fig. 1d and
Supplementary Table S2). This set of genes was strongly induced
at both 4 and 24 h of Candida stimulation and establishes a
deﬁnitive Candida-responsive signature distinct from that
observed with LPS, MTB or Borrelia stimulation.
Type I IFN SNPs modulate susceptibility to candidemia.
To assess whether the type I IFN genes speciﬁcally induced by
C. albicans in human leukocytes are indeed involved in antifungal
host defence, we investigated whether common polymorphisms
in a subset of these genes inﬂuence susceptibility to systemic
Candida infections. From a cohort of 217 Caucasian patients with
candidemia, well described elsewhere10,13, we had Immunochip
genotyping data available and 11 genes of the 101-transcript (95-
gene) data set were covered by the Immunochip array
(Supplementary Table S3). We tested these 11 genes for
association by taking immunochip data on 12,228 non-
candidemia Caucasian healthy volunteers as controls14. Analysis
of the loci associated with these 11 genes revealed signiﬁcant
association of genetic variation with susceptibility to systemic
candidiasis in four regions: CCL8 SNP 1kg_17_29697448
(P¼ 0.00069), STAT1 SNP rs16833172 (P¼ 0.0042), SP110 SNP
rs3769845 (P¼ 0.012) and PSMB8 SNP rs3198005 (P¼ 0.01)
(Fig. 2a–d; Supplementary Figs S1–S3, clusters 10, 11, 20, 11,
respectively) (Supplementary Table S3). After applying a
stringent Bonferroni correction for multiple testing, the
association between susceptibility to candidemia and STAT1
and CCL8 remained signiﬁcant. This ﬁnding conﬁrms that the
C. albicans-speciﬁc genes we identiﬁed in our transcriptional
arrays have an important role in host defence against systemic
fungal infections. We also attempted to assess whether the
polymorphisms in these genes also modiﬁed disease severity.
However, only 51 patients fulﬁlled the criteria of severe
candidiasis based on clinical scores and persistence of positive
blood cultures, and this number was too low for allowing the
identiﬁcation of signiﬁcant differences between genetic variation
and disease severity (disseminated disease, persistent fungemia
and mortality at 14 or 30 days) (data not shown).
Type I IFN SNPs modulate Candida-induced cytokine
responses. In an additional approach to validate the role of the
type I IFN pathway for host defence against Candida, we isolated
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PBMCs from an additional group of 74 healthy volunteers and
stimulated the cells with the fungus. Genetic variation in 11 type I
IFN pathway genes present on the Immunochip was correlated
with C. albicans-induced release of tumour-necrosis factor-a
(TNF-a), interleukin (IL)-1b, IL-8, IL-6, IL-10, IFN-g and IL-17.
In contrast to other microbial stimuli such as LPS and MTB,
C. albicans induced higher levels of TNF-a, IL-1b and IL-10
production, and lower levels of IL-8 and IL-6 in human PBMCs
(Supplementary Fig. S4). The correlation of cytokine concentra-
tions with genotypes at tag single nucleotide polymorphisms
(SNPs) of Candida-induced IFN pathway genes revealed sig-
niﬁcant associations at IRF1 and STAT1 regions (Fig. 3a–d) in
which IRF1 SNPs were associated with TNF-a (P¼ 0.0028) and
IL-10 levels (P¼ 0.0024), whereas STAT1 SNPs were associated
with TNF-a (P¼ 0.001) and IL-6 levels (P¼ 0.0002). Consistent
with the speciﬁcity of the type I IFN pathway for Candida
stimulation, the association was signiﬁcant with cytokine levels
induced by Candida, but not by LPS or MTB stimulation
(Supplementary Fig. S5).
Type I IFNs skew cytokine responses from Th17 towards
Th1. To investigate the importance of type I IFN signalling
in host defence against Candida, PBMCs from healthy
individuals were stimulated with heat-killed C. albicans.
In line with the transcriptional proﬁle described above (Fig. 1),
IFN-b could be detected in cell culture supernatants only
after C. albicans stimulation. In contrast, neither live (Fig. 4a),
nor heat-killed C. albicans induced any detectable IFN-a
production
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Figure 1 | Transcriptional responses to Candida. (a) K-means clustering identiﬁes shared and speciﬁc gene signatures in response to infection or
stimulation. For example, clusters 21 and 25 indicate common inﬂammatory genes (details in Supplementary Fig. S2) that are signiﬁcantly differentially
induced genes (Benjamini–Hochberg-adjusted Po0.05, fold change42) in response to B. burgdorferi, C. albicans, E. coli-derived LPS and Mycobacterium
tuberculosis (M.tb), compared with RPMI stimulations (Untreated), while clusters 7, 11 and 20 identify Candida-dominant response genes. Signal-to-noise
ratio relative to untreated is shown in the heatmap. (b) Using feature selection, naı¨ve Bayes classiﬁer and 10-fold cross-validation, a 101-transcript feature
set was identiﬁed from 693 differentially expressed transcripts shown in a, which distinguishes Candida from the other stimulants and an area under the
ROC (receiver-operating characteristic) curve of 97.8%, indicating a high discriminative value. The expression proﬁle (Z-transformed) of this feature set is
displayed. (c) Principal component analysis (PCA) of the Candida-response signature. Data from each individual sample is plotted along the three main
principal components (PC1, PC2, PC3). The three main principal components account for 45% of the total variance in gene expression. Samples from the
various stimulations and infections are colour coded as follows: C. albicans (2 h: bright red; 24 h: dark red), B. burgdorferi (Green), E. coli-derived LPS (Blue),
M.tb (Purple) and untreated (Yellow). (d) Enrichment analysis (MetaCore pathways) of the 101-transcript feature set reveals a striking enrichment of the
IFN signalling pathway. Supplementary Table S2 displays all the signalling/biological processes shown and their enrichment P-values.
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We next assessed the role of type I IFN pathways in the
induction of cytokines by C. albicans. When PBMCs were sti-
mulated with heat-killed C. albicans in the presence of an anti-
body against IFN-a/b/o receptor 1 (IFNAR), IFNg production
was signiﬁcantly lower compared with PBMCs stimulated in the
presence of a control antibody. Blocking of IFNAR did not
inﬂuence the production of the monocyte-derived cytokines
IL-b or TNF-a (Fig. 4b). Conversely, adding IFN-a or
IFN-b to Candida-stimulated cells increased IFN-g production,
while signiﬁcantly decreasing IL-17 and IL-22 production
(Fig. 4c). Together these data indicate that type I IFNs (in the
context of infection, most likely IFN-b) modulate the immune
reaction induced by C. albicans, skewing host defence towards a
Th1 response.
STAT1 mutations cause reduced expression of type I IFN
genes. Patients with autosomal-dominant CMC have increased
susceptibility to mucosal fungal infections and often carry gain-
of-function mutations in STAT1 (refs 15,16), which lead to
STAT1 hyperphosphorylation, that in turn likely makes STAT1
unavailable for forming heterodimers with other STAT
molecules17. In co-cultures of dendritic cells (DCs) and T cells
from CMC patients, this led to defective Th1 and Th17 responses
(Supplementary Fig. S6). To validate the role of Candida-speciﬁc
genes in human antifungal mucosal defence, we assessed the
expression of these genes in cells from CMC patients. PBMCs
from healthy controls and CMC patients were stimulated with
RPMI, E. coli-derived LPS, heat-killed C. albicans, or heat-killed
MTB. The expression of type I IFN pathway genes (including
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IRF5, IRF7, ISG15, IFI44 and IFI44L) that are induced
downstream of STAT1-STAT2 showed patterns of defective
expression in CMC patients compared with healthy controls,
supporting a role of the type I IFN pathway in this
immunodeﬁciency (Fig. 5). The expression of IRF3, IRF9 and
IFN-b, three genes in the type I IFN pathway upstream of
STAT1-STAT2, was not decreased in cells from CMC patients. In
fact, Candida-induced IFN-b expression appeared to be higher in
cells from CMC patients, possibly indicating a compensatory
feedback mechanism.
To investigate the type I IFN pathway in CMC patients in a
more systematic way, we also performed RNA sequencing
analysis in PBMCs stimulated with C. albicans from both
control volunteers and CMC patients. The differential
expression of 91 genes in response to C. albicans stimulation
was compared between CMC patients and healthy controls (10
genes from the 101-gene signature characteristic for Candida
were not considered: 7 because another isoform was already used
for FPKM (Fragments per Kilobase per Million mapped)
calculations, and 3 hypothetical proteins without concordant
refseq genes). In cells from healthy controls, two genes showed
downregulation (LFNG, RGC32), whereas all other genes were
upregulated upon stimulation (Supplementary Fig. S7), validating
the previous ﬁndings based on expression array analysis. To
observe differences between patients and controls, the
standardized fold change was used to create the respective
heatmap (Fig. 6). The patients show a much lower standardized
fold change in genes downstream of STAT1, again supporting the
role of type 1 IFN pathway in CMC. We found 27 genes, from the
set of 91 genes, to be signiﬁcantly differently regulated upon
Candida stimulation in patients compared with controls based on
an analysis of variance (ANOVA) analysis (P-value interaction
group and treatment o0.05) (MX1, OAS3, IFIT2, RTP4, XAF1,
OAS2, IFI44, IFIH1, IFIT3, ADAR, PRIC285, FAM46A, SAMD9L,
EIF2AK2, PARP12, TRIM22, ZBP1, HERC6, RSAD2, IFNG,
OAS1, STAT2, DHX58, IRF7, TNFSF10, ISG15, HERC5).
To determine the role of these 27 genes we calculated Gene
ontology enrichment scores using the Database for Annotation,
Visualization and Integrated Discovery. Enriched gene clusters
were generated using Functional Annotation Clustering. Gene
ontology terms associated with response to type I IFN and viral
infections showed signiﬁcant enrichment (P¼ 1.09 10 14)
(Supplementary Table S4).
Discussion
The last decade has witnessed a signiﬁcant increase in knowledge
related to the mechanisms involved in antifungal host defence.
However, most of this knowledge is based on in vitro and animal
studies; these studies led to hypotheses to be tested in human
systems, leading to a somewhat biased view of human immunity
against fungi. In the present study we have used a different
approach based exclusively on complementary human studies:
transcriptomics analysis in human primary cells, correlation of
genetic variability and antifungal immunity in healthy volunteers
(functional genomics), case–control association studies in
patients with disseminated C. albicans infections and assessment
of antifungal immunity in CMC patients.
In our initial approach, we designed a hypotheses-generating
set of experiments by assessing the transcriptional proﬁle induced
in circulating primary leukocytes by C. albicans. Human primary
PBMCs were stimulated either with C. albicans or with other
inﬂammatory stimuli. Pathway analysis of the genes induced by
Candida indicated two broad categories: (i) a ﬁrst set of genes that
was strongly induced and shared by both C. albicans and other
inﬂammatory stimuli (LPS, MTB or B. burgdorferi), constituted
expected pathways involved in inﬂammation and innate immu-
nity, many of which have important roles in antifungal
immunity18, and (ii) a feature set comprising an expression
signature of 101 transcripts (95 genes) that distinguishes the
Candida-speciﬁc response and is characterized by a strikingly
strong and unanticipated type I IFN response.
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Because the identiﬁcation of the type I IFN pathway as the
most prominent Candida-speciﬁc transcriptional signature was
surprising, we initiated a series of studies to conﬁrm this ﬁnding.
First, we assessed whether genetic polymorphisms in several of
the genes identiﬁed in the Candida-speciﬁc data set inﬂuenced
susceptibility to systemic Candida infections. In a cohort of
patients with candidemia that were genotyped using the
Immunochip platform (Illumina14), on which 11 genes of the
Candida-speciﬁc data set were covered, we identiﬁed signiﬁcant
association of genetic variation with susceptibility to candidiasis
in four of these genes: CCL8 locus, STAT1, SP110 locus and
PSMB8 locus. This ﬁnding conﬁrms that genes from the 101
Candida-speciﬁc data set inﬂuence susceptibility to systemic
fungal infections.
Second, the role of the type I IFN pathway for the anti-Candida
immune response was subsequently validated in a study in which
PBMCs isolated from a group of healthy volunteers were
stimulated with the fungus. Genetic variation in the 11 type I
IFN pathway genes present on the Immunochip was correlated
with C. albicans-induced cytokine production. The correlation of
cytokine concentrations with genotypes at tag SNPs of Candida-
induced IFN pathway genes revealed signiﬁcant associations at
IRF1 and STAT1 regions, both crucial components of type I IFN
pathway. We cannot exclude, however, that the effect of these
polymorphisms on TNF-a production are exerted through type II
IFNs; IFNg is stimulated by type I IFNs19, and is known to induce
TNF-a production20. These data support the hypothesis of the
speciﬁcity of the type I IFN pathway for Candida stimulation, as
this association was signiﬁcant only for cytokine production
induced by Candida, but not by other stimuli.
Third, we performed classical immunological studies to
assess the role of type I IFNs for Candida-induced immune
responses, and we demonstrated that type I IFNs induced by
Candida modulate Th1/Th17 cytokine proﬁles; IFNa and IFNb
increased IFNg production, while decreasing IL-17 production.
Moschen et al.21 previously demonstrated that type I IFNs
decrease IL-17 production in vitro and in vivo. TNF-a production
did not seem to be inﬂuenced by blocking the IFNAR, suggesting
that genetic effects in STAT1 exert their effect on
TNF-a production either through direct intracellular pathways,
or indirectly through IFNg. Interestingly, C. albicans seems to
induce only IFN-b, rather than IFN-a, consistent with earlier
studies in mice22,23.
Finally, using both quantitative PCR and RNA sequencing
analysis, we demonstrated that the expression of type I IFN
pathway-induced genes was defective in CMC patients harbour-
ing a gain-of-function mutation in STAT1 (ref. 15). These
mutations lead to increased STAT1 phosphorylation and IFNg
signalling. Liu et al.16 demonstrated increased STAT1
phosphorylation in response to IFNg stimulation in U3C cells
transfected with mutated STAT1. They hypothesize that IFN-
targeted genes can lead to decreased IL-17 production. However,
freshly isolated PBMC from CMC patients do not produce any
IFNg in response to C. albicans stimulation15. Therefore, it is
more likely that the inability of mutated STAT1 to form
heterodimers with STAT3 and STAT4 causes defective Th1/
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Figure 5 | Expression of type I IFN pathway genes in patients with a STAT1 mutation. Reduced expression of type I IFN pathway genes in patients with a
STAT1 mutation (n¼ 2, with patients measured twice), and healthy controls (n¼8). A total of 5 105 PBMC in a volume of 200ml, were stimulated for
24 h, with RPMI, E. coli-derived LPS (10 ngml 1), heat-killed C. albicans (1 106ml 1), or heat-killed MTB (1mgml 1). mRNA was isolated from cell lysates
using TRIzol. Transcription of IFN-b, IRF3, IRF9, IRF5, IRF7, ISG15, IFI44 and IFI44L was measured using quantitative PCR. Data are presented as
meanþ s.e.m.
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Th17 responses17, which are likely to represent the main
immunological defect in this disease. Additional defects in the
expression of type I IFN-induced genes, as shown here, may also
contribute to the increased susceptibility to mucosal fungal
infections. Whether this is truly caused by a defect in STAT1-
STAT2 heterodimerization remains to be demonstrated.
Taken together, these complementary studies represent a
compelling body of evidence that the type I IFN pathway is an
important component of the immune response during infections
with C. albicans in humans. Moreover, the data presented here
are supported by emerging information from murine studies. For
example, Bourgeois et al.22 and Biondo et al.23 have reported that
mouse conventional DCs produce IFN-b upon stimulation with
Candida spp. and have proposed a role for MyD88, TLR7 and
TLR9 in this induction. On the other hand, these results are
relatively surprising, as no earlier study has reported a role for
type I IFNs in human antifungal host defence. In this respect,
primary immunodeﬁciencies in type I IFN pathway are mainly
associated with viral, rather than fungal, infections24. Therefore,
our data indicate that type I IFN defects determine an increase
susceptibility risk for fungal infections, as demonstrated here by
the association with candidemia in risk groups, rather than an
overt immunodeﬁciency associated with severe fungal infections.
The precise effect of type I IFNs for anti-Candida host defence
is still being debated. One study in type I IFNAR knockout mice
suggested a deleterious role for this pathway22, whereas another
study reported that IFNAR / mice die from their inability to
control fungal growth23. Although type I IFNs have an important
role in the immune response against viral infections25, they seem
to be deleterious in bacterial infections26. In humans with
Candida infections, the role of type 1 IFNs is not yet settled,
although the defects seen in type I IFN gene expression in CMC
patients, the susceptibility to candidemia by STAT1
polymorphisms, and the potentiation of Th1 responses by type
I IFNs, all suggest a beneﬁcial effect of the type I IFN pathway in
human antifungal host defence.
Although viruses have long been known to induce
type I IFN production, other microorganisms have been recently
reported to induce this pathway. MTB stimulation induces the
expression of IFNB and IFNA1 in human macrophages27 and in
murine bone marrow-derived macrophages28; type I IFNs are
required for caspase-1 activation during Francisella tularensis
infection29; and Listeria monocytogenes induces the transcription
of IFNB in macrophages30. However, the complete transcriptional
proﬁle of the type I IFN pathway performed here shows
important differences from the type I IFN proﬁle induced by
MTB 31 and is signiﬁcantly more pronounced for Candida
than for MTB (Supplementary Fig. S4). Interestingly, the very
strong induction of type I IFN pathway genes by Candida may
explain the well-known, yet unexplained, beneﬁcial effects of
injecting Candida-derived extracts for the treatment of warts in
patients32,33.
In summary, this work presents complementary arguments
from several studies to propose that the type I IFN pathway has
an important role in the immune responses to the fungal
pathogen C. albicans in humans. The cross-validation between
these approaches supports the value of this systems biology
approach, combining transcriptomics with functional genomics
and immunological data. Using this approach, we have conﬁrmed
the role of pathways known to be involved in antifungal host
defence (for example, common inﬂammatory pathways and
the Th1/Th17 pathways) and we have identiﬁed a novel pathway
(the type I IFN pathway). It is expected that this knowledge will
have an important contribution in devising novel immunother-
apeutic strategies for fungal infections, as well as inﬂuencing
decision-making for vaccine design.
Methods
Study populations. For assessing the transcriptome and the cytokine production
capacity, blood was collected after written informed consent from healthy volun-
teers. Adult patients with candidemia were enroled after informed consent (or
waiver as approved by the Institutional Review Board) at the Duke University
Hospital (DUMC, Durham, North Carolina, USA) and Radboud University Nij-
megen Medical Centre (RUNMC, Nijmegen, The Netherlands). The study was
approved by the Institutional Review Boards at each study centre, and enrolment
occurred between January 2003 and January 2009 (ref. 34). The study was
performed in accordance with the declaration of Helsinki. In addition, blood was
collected from two patients with CMC (on two different occasions) and eight
healthy controls to investigate the induction of IFN genes by Candida. After
informed consent was given, blood was collected by venipuncture into 10ml EDTA
syringes (Monoject, s-Hertogenbosch, The Netherlands).
PBMC isolation. Separation and stimulation of PBMCs was performed as
described previously35. Brieﬂy, the PBMC fraction was obtained by density
centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) over
Ficoll–Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed twice in
saline and suspended in culture medium. The cells were counted in a
haemocytometer and their number was adjusted to 5 106ml 1.
Cell stimulation. For the transcriptome analysis, cells were stimulated for 4 or 24 h
with RPMI, heat-killed B. burgdorferi36, C. albicans (UC 820) (1 106ml 1)37,
MTB (1 mgml 1) or E. coli-derived LPS (10 ngml 1). To correlate cytokine
production to SNPs in the type I IFN pathway, 5 105 PBMCs from healthy
volunteers were stimulated with heat-killed C. albicans (1 106ml 1) for 24 h. To
investigate the effect of type I IFNs on cytokine production, 5 105 PBMCs were
stimulated with heat-killed C. albicans (1 106ml 1) in the absence or presence
of IFN-a2b (1 105Uml 1) (IntronA, SP Labo N.V., Heist-op-den-berg,
Belgium), IFN-b (10 ngml 1) or anti-IFNAR (100 ngml 1) (21385-1, PBL
Inferon Source, Piscataway, USA). To assess the development of Th1 and Th17
cells, a total of 1 106 mononuclear cells were added to 96-well ﬂat-bottom plates
(Greiner). Subsequently, the monocytes within the PBMC pool were differentiated
towards DCs by addition of IL-4 (50 ngml 1, R&D Systems), GM-CSF
(50 ngml 1, R&D Systems) and 10% human serum for 7 days. After every
second day, half of the medium was replaced by fresh DC differentiation medium.
At day 7 of the culture, cells were stimulated with 1 106 Candida conidia for
another 6 days.
Transcriptome analysis. Global gene expression was proﬁled using Illumina
Human HT-12 Expression BeadChip according to manufacturer’s instructions.
Image analysis, bead-level processing and quantile normalization of array data were
performed using the Illumina LIMS platform, BeadStudio. A gene-wise linear
model was ﬁtted to the data and was performed in R programming language
(http://www.r-project.org/), utilizing functions from Linear Models for Microarray
Data38. For each probe, a moderated t-statistic (with s.e. moderated across genes)
was computed using a Bayesian model. The associated P-values were adjusted to
control the false discovery rate in multiple testing, using the BH method39. For
each transcript, Signal-to-Noise ratios (SNR) were computed for each infection or
stimuli group relative to the untreated (RPMI) control group. The expression SNR
proﬁles of transcripts identiﬁed as differentially expressed (BH-adjusted Po0.05
and fold-change 42 ) were clustered using the K-means algorithm40. We
performed feature (attribute) selection41,42 on differentially expressed transcripts
using Information Gain (Kullback–Leibler divergence or relative entropy) to
identify discriminatory features or transcripts that are most informative of the state
of infection or stimulation. The accuracy of class prediction using a Java
implementation of a naı¨ve Bayes classiﬁer42,43 incorporating these features was
evaluated using 10-fold cross-validation.
Cytokine measurements. The concentration of IL-1b, IL-17, IL-22, TNF-a (R&D
Systems, Abingdon, UK), IL-6, IL-8, IL-10, IFN-g (Sanquin, Amsterdam, the
Netherlands) and IFN-a, IFN-b (PBL Interferon Source, Piscataway, USA) was
measured in cell culture supernatants using enzyme-linked immunosorbent assay
according to the instructions of the manufacturer.
SNP selection. DNA was isolated using the Gentra Pure Gene Blood kit (Quiagen,
Venlo, The Netherlands), according to the protocol of the manufacturer. Illumina
Immunochip is a custom-designed high-density array to densely genotype 186 loci
associated with 12 different autoimmune or inﬂammatory diseases reaching gen-
ome-wide association study signiﬁcance threshold (Po5 10 8)14. The
candidemia cohort and volunteers DNA samples were genotyped on this
Immunochip Illumina platform. Only SNPs in 11 of the 101-gene data set
identiﬁed earlier were studied, as the other genes were not represented on the
Immunochip. We selected tag-SNPs (Supplementary Table S3) at each region that
are located within ±250 kb of the locus by employing Haploview44 and we
excluded SNPs with r2Z0.8 from association analysis.
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Statistical analysis. Analyses were performed using PLINKv1.07 (refs 45,46). We
performed Multidimensional scaling (MDS) analysis to reveal genetic background
of cases and controls in Candidemia cohort (Supplementary Fig. S8). The
association between tag-SNPs and Candidemia susceptibility was tested by logistic
regression with the ﬁrst four components from MDS analysis as covariates. The
correlation between cytokine levels and genotypes was tested by Wilcoxon rank
sum test using R. Po0.05 was considered signiﬁcant.
Real-time PCR. Two million freshly isolated PBMCs were incubated with various
stimuli as described above. After 24 h of incubation at 37 1C, total RNA was extracted
in 800ml of TRIzol reagent (Invitrogen, Breda, The Netherlands). Isolated RNA was
reverse-transcribed into complementary DNA using oligo(dT) primers and MMLV
reverse transcriptase. PCR was performed using a 7300 Real-Time PCR system
(Applied Biosystems, Lennik, Belgium). Primer sequences for human IFN-b: sense:
50-ATG-ACC-AAC-AAG-TGT-CTC-CTC-C-30 and antisense: 50-GGA-ATC-CAA-
GCA-AGT-TGT-AGC-TC-30 ; IRF9: sense 50-GAT-ACA-GCT-AAG-ACC-ATG-
TTC-CG-30and antisense: 50- TGA-TAC-ACC-TTG-TAG-GGC-TCA-30 ; IRF7:
sense: 50-GCT-GGA-CGT-GAC-CAT-CAT-GTA-30 and antisense: 50-GGG-CCG-
TAT-AGG-AAC-GTG-C-30; ISG15: sense: 50-CGC-AGA-TCA-CCC-AGA-AGA-
TCG-30 and antisense: 50-TTC-GTC-GCA-TTT-GTC-CAC-CA-30 ; IFI44: sense:
50-ATG-GCA-GTG-ACA-ACT-CGT-TTG-30 and antisense: 50-GCA-GGA-TCT-
TTC-GTG-CAA-CC-30 ; IFI44L: sense: 50-AGG-GAA-TCA-TTT-GGC-TCT-GTA-
GA-03 and antisense: 50-AGC-CGT-CAG-GGA-TGT-ACT-ATA-AC-30 ; IRF3:
sense: 50-AGA-GGC-TCG-TGA-TGG-TCA-AG-30 and antisense: 5-AGG-TCC-
ACA-GTA-TTC-TCC-AGG-30 ; IRF5: sense: 50-GGG-CTT-CAA-TGG-GTC-AAC-
G-30 and antisense: 50-GCC-TTC-GGT-GTA-TTT-CCC-TG-30 . B2M was used as a
reference gene, for which the primers were: 50-ATG-AGT-ATG-CCT-GCC-GTG-
TG-30 (forward) and 50-CCA-AAT-GCG-GCA-TCT-TCA-AAC-30 (reverse). The
PCR conditions were as follows: 2min at 50 1C and 10min at 95 1C, followed by 40
cycles of PCR reaction at 95 1C for 15 s, and 60 1C for 1min.
RNA sequencing. RNA sequencing experiments were performed on 4 h unsti-
mulated and C. albicans-stimulated PBMC from three healthy controls and two
CMC patients. Total RNA was isolated as described above. The RNA integrity
(RNA integrity scoreZ7) was measured on the Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, USA) using an Agilent RNA 6000 Pico Chip according to the man-
ufacturer’s instructions. Enrichment of mRNA was done using the Micro-
Poly(A)Purist Kit (Ambion, Life Technologies, Foster City, USA) according to
manufacturer’s instructions, starting with 5 mg of total RNA and using two rounds
of Oligo(dT) selection. Whole transcriptome library preparation was performed
using the SOLiD Total RNA-Seq Kit (STaR Kit, Life Technologies) and the cor-
responding low input amount protocol (version July 2011, Life Technologies). In
brief, 25 ng high-quality poly(A) RNA was fragmented by RNAse III digestion,
cleaned up using the PureLink RNA Micro Kit (Invitrogen, Life Technologies) and
checked for quantity and size-distribution on a Agilent 2100 Bioanalyzer. RNA
adapters were hybridized and ligated to the fragmented RNA, followed by reverse
transcription. After puriﬁcation and size-selection of cDNA using Agencourt
AMPure XP Reagent beads, the cDNA was ampliﬁed and used as input for the
SOLiD system bead preparation using the SOLiD Easy bead system (E120 scale).
Paired-end sequencing (50þ 25 bases) was performed on one ﬂowcell of a 5500XL
sequencer (Life Technologies) For each sample deep sequencing was performed
resulting in a sequencing depth ranging from 75.6 to 105.5 million paired-end
reads. Paired-end colorspace reads were mapped against the human genome (hg19)
using Tophat (version 1.4.1)47. To increase mapping performance a gene transfer
format (GTF) ﬁle containing the exon boundries of all known RefSeq genes (25,024
genes) was supplied to Tophat and the insert size was set to 110 bases. For all genes
FPKM values were calculated using Cufﬂinks (version 2.0.0)48. Further statistical
analyses was done using Partek Genomic Suite software (version 6.6, build
6.12.0109, Partek Inc., St Louis, USA). Fold changes and P-values were calculated
for each gene by performing a multifactorial ANOVA on log2 (with an offset of
1.0) transformed FPKM expression values. Factors included in the ANOVA model
were group (patient or control), treatment (stimulation status), individual (data
from same individual) and the interaction between group and treatment. Fold
changes for the heatmaps were calculated for each individual by dividing the FPKM
expression values of the C. albicans-stimulated sample by the unstimulated (RPMI)
sample. Fold changes with valueso1 were replaced by the negative of the inverse.
A gene list containing 101 differentially expressed transcripts known from the
expression array was used to select genes for further downstream analysis. Of this
list, 10 transcripts were not considered; 7 because another isoform was already used
for FPKM calculations and 3 hypothetical proteins without concordant refseq
genes.
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